Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function
暂无分享,去创建一个
[1] M. Lutz,et al. Myeloid‐derived suppressor cell activation by combined LPS and IFN‐γ treatment impairs DC development , 2009, European journal of immunology.
[2] M. Manns,et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor , 2009, Hepatology.
[3] P. Sinha,et al. Inflammation enhances myeloid‐derived suppressor cell cross‐talk by signaling through Toll‐like receptor 4 , 2009, Journal of leukocyte biology.
[4] D. Kerr,et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma , 2009, Hepatology.
[5] J. Talmadge,et al. Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice , 2009, Cancer Immunology, Immunotherapy.
[6] W. Nacken,et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.
[7] M. Manns,et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. , 2008, Gastroenterology.
[8] I. Borrello,et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. , 2008, Cancer research.
[9] V. Bronte,et al. Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.
[10] S. Rafii,et al. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. , 2008, Cancer cell.
[11] H. Zhang,et al. In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells. , 2007, World journal of gastroenterology.
[12] G. Fuh,et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.
[13] S. Albelda,et al. Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response1 , 2007, The Journal of Immunology.
[14] J. Kappes,et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. , 2007, Blood.
[15] J. Califano,et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function , 2006, The Journal of experimental medicine.
[16] Paolo Serafini,et al. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.
[17] D. Gabrilovich,et al. Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells1 , 2005, The Journal of Immunology.
[18] F. Brombacher,et al. Reactive Oxygen Species and 12/15-Lipoxygenase Contribute to the Antiproliferative Capacity of Alternatively Activated Myeloid Cells Elicited during Helminth Infection 1 , 2005, The Journal of Immunology.
[19] P. Sinha,et al. Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.
[20] Michael Karin,et al. NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.
[21] D. Gabrilovich. Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.
[22] J. Bruix,et al. Focus on hepatocellular carcinoma. , 2004, Cancer cell.
[23] D. Carbone,et al. Tumor-host immune interactions and dendritic cell dysfunction. , 2004, Advances in cancer research.
[24] A. Yang,et al. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. , 2003, Cancer research.
[25] M. Huang,et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] G. Trinchieri,et al. Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.
[27] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[28] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[29] Yao-Jun Qu,et al. Influence of granulocyte macrophage colony stimulating factor and tumor necrosis factor on anti-hepatoma activities of human dendritic cells. , 2000, World journal of gastroenterology.
[30] D. Carbone,et al. Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] T. Ishikawa,et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection , 2000, Journal of gastroenterology and hepatology.
[32] N. Horiike,et al. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. , 2000, Cancer letters.
[33] P. Hwu,et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. , 1999, Journal of immunology.
[34] F. Chisari,et al. Immune Pathogenesis of Hepatocellular Carcinoma , 1998, The Journal of experimental medicine.
[35] J. Banchereau,et al. Recent advances in the study of dendritic cells and follicular dendritic cells. , 1995, Immunology today.
[36] R. Steinman,et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.